Literature DB >> 31305179

Key considerations in the pharmacotherapy of tuberculous meningitis.

Sean Wasserman1,2, Angharad Davis1,3,4, Robert J Wilkinson1,4,5, Graeme Meintjes1,2.   

Abstract

Entities:  

Keywords:  Aspirin; Corticosteroids; Host-directed therapies; Linezolid; Rifampicin; Thalidomide; Tuberculous meningitis

Year:  2019        PMID： 31305179      PMCID： PMC6763362          DOI： 10.1080/14656566.2019.1638912

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  24 in total

1.  Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Authors:  David M Tobin; Francisco J Roca; Sungwhan F Oh; Ross McFarland; Thad W Vickery; John P Ray; Dennis C Ko; Yuxia Zou; Nguyen D Bang; Tran T H Chau; Jay C Vary; Thomas R Hawn; Sarah J Dunstan; Jeremy J Farrar; Guy E Thwaites; Mary-Claire King; Charles N Serhan; Lalita Ramakrishnan
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

Authors:  Rovina Ruslami; A Rizal Ganiem; Sofiati Dian; Lika Apriani; Tri Hanggono Achmad; Andre J van der Ven; George Borm; Rob E Aarnoutse; Reinout van Crevel
Journal:  Lancet Infect Dis       Date:  2012-10-25       Impact factor: 25.071

3.  Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.

Authors:  U K Misra; J Kalita; P P Nair
Journal:  J Neurol Sci       Date:  2010-04-24       Impact factor: 3.181

4.  The role of aspirin in childhood tuberculous meningitis.

Authors:  Johan F Schoeman; Anita Janse van Rensburg; Jacoba A Laubscher; Priscilla Springer
Journal:  J Child Neurol       Date:  2011-05-31       Impact factor: 1.987

Review 5.  Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.

Authors:  P R Donald
Journal:  Tuberculosis (Edinb)       Date:  2010-08-14       Impact factor: 3.131

Review 6.  HIV-associated tuberculous meningitis--diagnostic and therapeutic challenges.

Authors:  Suzaan Marais; Dominique J Pepper; Ben J Marais; M Estée Török
Journal:  Tuberculosis (Edinb)       Date:  2010-09-28       Impact factor: 3.131

7.  Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors:  Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

8.  Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role.

Authors:  J F Schoeman; P Springer; A Ravenscroft; P R Donald; L G Bekker; A J van Rensburg; W A Hanekom; P A Haslett; G Kaplan
Journal:  J Child Neurol       Date:  2000-08       Impact factor: 1.987

9.  Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa.

Authors:  Gijs T J van Well; Berbe F Paes; Caroline B Terwee; Priscilla Springer; John J Roord; Peter R Donald; A Marceline van Furth; Johan F Schoeman
Journal:  Pediatrics       Date:  2009       Impact factor: 7.124

10.  Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study.

Authors:  Johan F Schoeman; Priscilla Springer; Anita Janse van Rensburg; Sonja Swanevelder; Willem A Hanekom; Patrick A J Haslett; Gilla Kaplan
Journal:  J Child Neurol       Date:  2004-04       Impact factor: 1.987
View more
  3 in total

1.  Management of intracranial tuberculous mass lesions: how long should we treat for?

Authors:  Suzaan Marais; Ronald Van Toorn; Felicia C Chow; Abi Manesh; Omar K Siddiqi; Anthony Figaji; Johan F Schoeman; Graeme Meintjes
Journal:  Wellcome Open Res       Date:  2019-10-31

Review 2.  Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.

Authors:  Ranjeet Kumar; Afsal Kolloli; Pooja Singh; Christopher Vinnard; Gilla Kaplan; Selvakumar Subbian
Journal:  Front Cell Infect Microbiol       Date:  2020-01-14       Impact factor: 5.293

3.  Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.

Authors:  Sean Wasserman; Angharad Davis; Cari Stek; Maxwell Chirehwa; Stephani Botha; Remy Daroowala; Marise Bremer; Mpumi Maxebengula; Sonya Koekemoer; Rene Goliath; Amanda Jackson; Thomas Crede; Jonathan Naude; Patryk Szymanski; Yakoob Vallie; Muhammed S Moosa; Lubbe Wiesner; John Black; Graeme Meintjes; Gary Maartens; Robert J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.